Edition:
United States

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

704.75INR
18 Aug 2017
Change (% chg)

Rs1.25 (+0.18%)
Prev Close
Rs703.50
Open
Rs703.00
Day's High
Rs709.85
Day's Low
Rs687.60
Volume
1,514,532
Avg. Vol
3,233,998
52-wk High
Rs895.00
52-wk Low
Rs503.05

Latest Key Developments (Source: Significant Developments)

India's Aurobindo Pharma June-qtr consol profit down about 11 pct
Wednesday, 9 Aug 2017 08:14am EDT 

Aug 9 (Reuters) - Aurobindo Pharma Ltd ::June quarter consol net profit 5.19 billion rupees versus 5.85 billion rupees last year.Consensus forecast for June quarter consol net profit was 5.67 billion rupees.June quarter consol net sales 36.21 billion rupees versus 37.05 billion rupees last year.  Full Article

Aurobindo Pharma gets USFDA approval for Sevelamer Carbonate tablets
Tuesday, 18 Jul 2017 11:40pm EDT 

July 19 (Reuters) - Aurobindo Pharma Ltd :Says Aurobindo Pharma receives USFDA approval for Sevelamer Carbonate tablets.Says product is being launched immediately.Drug indicated for control of serum phosphorus in patients with chronic kidney disease on dialysis.  Full Article

Aurobindo Pharma gets USFDA approval for drug for treating chronic kidney disease
Thursday, 15 Jun 2017 12:53am EDT 

June 15 (Reuters) - Aurobindo Pharma Ltd :Aurobindo Pharma - receives USFDA approval for Sevelamer Carbonate Oral Suspension.Aurobindo Pharma - product is being launched immediately.Aurobindo Pharma - drug used for treatment of patients with chronic kidney disease.  Full Article

U.S. FDA says approves first generic versions of Strattera
Tuesday, 30 May 2017 04:36pm EDT 

May 30 (Reuters) - Glenmark Pharmaceuticals Ltd :U.S. Food and Drug Administration says approved first generic versions of Strattera for attention-deficit/hyperactivity disorder in pediatric, adult patients‍​.U.S. FDA says Apotex, Teva Pharmaceuticals USA, Aurobindo Pharma, Glenmark Pharmaceuticals gained approval to market Atomoxetine in multiple strengths.  Full Article

Aurobindo Pharma expects U.S. drug price erosion to continue for at least another 4 qtrs - exec
Tuesday, 30 May 2017 12:09am EDT 

May 30 (Reuters) - Aurobindo Pharma Ltd :Exec says expects U.S. drug price erosion to continue for at least another four quarters.Exec says price erosion in U.S. here to stay; only the fittest, with a broad number of drug applications will survive..  Full Article

Aurobindo Pharma says US FDA issued form 483 with 6 observations for unit-III
Wednesday, 19 Apr 2017 05:11am EDT 

April 19 (Reuters) - Aurobindo Pharma Ltd :Clarifies on news item "US FDA issues 5-6 'largely procedural' observations to Aurobindo Pharma's Unit-III".Says have been issued a form 483 with 6 observations.Observations are all on procedural improvements.Says none of observations related to data integrity.  Full Article

Aurobindo Pharma gets FDA nod for generic drug to treat HIV-1 infection
Thursday, 30 Mar 2017 12:58am EDT 

Aurobindo Pharma Ltd : Says Aurobindo Pharma receives USFDA approval for generic Epzicom tablets . Says product being launched immediately .Says tablets intented to treat HIV-1 infection.  Full Article

Aurobindo Pharma gets USFDA nod for Meropenem injection
Tuesday, 28 Mar 2017 12:10am EDT 

Aurobindo Pharma Ltd : Says co gets USFDA approval for Meropenem injection . Meropenem injection is a generic equivalent of Astrazeneca Pharma's Merrem injection .Drug indicated to treat complicated skin & skin structure infections, complicated intra-abdominal infections & bacterial meningitis.  Full Article

Aurobindo Pharma gets FDA nod for generic version of Reckitt Benckiser’s Mucinex DM tablets
Monday, 20 Mar 2017 08:27am EDT 

Aurobindo Pharma Ltd : Says Aurobindo Pharma receives USFDA approval for guaifenesin and dextromethorphan hydrobromide . Says the product will be launched in Q1FY18. . guaifenesin and dextromethorphan hydrobromide extended-release tablets are AB rated generic equivalent of Reckitt Benckiser’S Mucinex DM tablets .Guaifenesin and dextromethorphan hydrobromide extended-release tablets helps loosen mucus and phlegm, and thin out bronchial secretions.  Full Article

Aurobindo Pharma says co became aware of complaint from numerous states filed in Connecticut
Friday, 16 Dec 2016 02:46am EST 

Aurobindo Pharma Ltd : says co became aware of complaint from numerous states filed in Connecticut . says received subpoena in mar 2016 requesting non-product specific information . says have not received any further requests for information or subpoenas after March 2016 subpoena .says sales of Glyburide by our US subsidiary is not material.  Full Article

UPDATE 1-Aurobindo Pharma Q1 profit drops 11 pct, misses estimates

Aug 9 Indian drugmaker Aurobindo Pharma Ltd reported a 11 percent fall in quarterly profit, hurt by lower sales from its formulations business in the U.S. and pre-launch disruptions of a pan-India tax reform.